Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06975787
PHASE1

Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

Sponsor: Regeneron Pharmaceuticals

View on ClinicalTrials.gov

Summary

This study is researching a particular group of experimental drugs administered for a short period in the treatment of patients with Lupus Nephritis (LN). The main aim of the current study is to see how safe and tolerable the study drugs are in a long-term follow-up. This is a main study, called an umbrella study, which includes several independent smaller sub-studies. Each of these smaller main sub-studies tests different drugs at the same time, all aimed at treating LN. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times * Whether the body makes antibodies against the study drug (which could make the drug less effective or could lead to side effects)

Official title: A Dose Escalation Study Investigating Bispecific Antibody Therapy in Patients With Lupus Nephritis

Key Details

Gender

All

Age Range

18 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2025-12-22

Completion Date

2028-07-23

Last Updated

2026-03-25

Healthy Volunteers

No

Interventions

DRUG

Vonsetamig

Administered as per the protocol

DRUG

Odronextamab

Administered as per the protocol

Locations (6)

Mayo Clinic

Rochester, Minnesota, United States

University Medical Center of the Johannes Gutenberg-University Mainz

Mainz, Germany

Seoul National University Hospital

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Changhua Christian Hospital

Changhua, Taiwan

Taipei Veterans General Hospital

Taipei, Taiwan